O elenco foi anunciado para a próxima apresentação workshop em Nova York do novo musical SATELLITES, com livro, música e letras de Zack Zadek, direção musical de Madeline Benson, design de som do ...
CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Elaine Chen covers biotech, co-writes The Readout newsletter, and ...
Novo Nordisk remains a Strong Buy despite recent earnings misses, trial setbacks, and competitive pressures in the weight loss/diabetes market. NVO's valuation is compelling, trading at a low P/E of ...
Novo Nordisk said a weight-loss drug candidate helped patients lose weight and reduce blood-sugar levels in pill and injection forms during a mid-stage trial, lifting shares in the company. The Danish ...
Novo Nordisk has come up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease (AD). But perhaps the larger story associated with the unsurprising result is the market ...
Quantos anos você tem? Segundo a retrospectiva do Spotify, a resposta pode não ter nada a ver com a sua data de nascimento. O novo recurso da plataforma, denominado "idade musical", apresenta uma ...
Amycretin targets GLP-1 and amylin hormones, seen as potential best-in-class therapy Novo shares rise over 5% after amycretin trial results Amycretin aids significant weight loss and glucose control ...
SAN DIEGO Dec 2 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and ...
Novo Nordisk said on Monday an older oral version of its semaglutide drug failed to meet its main goal in late-stage trials testing whether the medicine can slow cognitive decline in Alzheimer’s ...
Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says
An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, drugmaker Novo Nordisk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback